EGFR and pancreatic neoplasm: This combination will be evaluated in various cancer patients, for example in NSCLC patients containing mutations at EGFR who have progressed after treatment with EGFR inhibitors or with patients with triple negative breast, CRC, melanoma, and pancreatic cancers.